We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
Read MoreHide Full Article
AbbVie Inc. (ABBV - Free Report) announced that it has acquired Seattle-based, privately held company Mavupharma to develop novel treatments for cancer using the latter’s STING signaling pathway. The acquisition is expected to enhance AbbVie’s early-stage oncology pipeline. Financial terms of the deal have been kept under wraps.
Mavupharma's lead candidate, MAVU-104, is an orally active, small molecule that inhibits an enzyme involved in the regulation of the STING pathway known as ENPP1.
Shares of AbbVie have declined 23.7% so far this year, underperforming the industry’s decrease of 1.5%.
Oncology is a key therapeutic area for AbbVie and the company believes that it will be its major driver over the next 10 years. Key drugs in its oncology portfolio are Imbruvica, currently approved for quite a few indications and marketed in partnership with J&J (JNJ - Free Report) , and Venclyxto/Venclexta, approved to treat chronic lymphocytic leukemia (CLL) and marketed in partnership with Roche (RHHBY - Free Report) .
Several studies on Imbruvica are underway to evaluate the drug alone or in combination across different patient segments. AbbVie is also studying Venclyxto/Venclexta to expand its label to address a broader relapsed/refractory CLL patient population, extend into earlier lines of therapy and cover other hematologic malignancies like multiple myeloma and acute myeloid leukemia (AML).
Notably, other companies are also exploring opportunities to develop novel therapies using the STING activator platform. For instance, AduroBioTech has an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
Further, Aduro has a collaboration and license deal with Novartis for developing and commercializing STING activator candidates in its oncology pipeline.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie Inc. (ABBV - Free Report) announced that it has acquired Seattle-based, privately held company Mavupharma to develop novel treatments for cancer using the latter’s STING signaling pathway. The acquisition is expected to enhance AbbVie’s early-stage oncology pipeline. Financial terms of the deal have been kept under wraps.
Mavupharma's lead candidate, MAVU-104, is an orally active, small molecule that inhibits an enzyme involved in the regulation of the STING pathway known as ENPP1.
Shares of AbbVie have declined 23.7% so far this year, underperforming the industry’s decrease of 1.5%.
Oncology is a key therapeutic area for AbbVie and the company believes that it will be its major driver over the next 10 years. Key drugs in its oncology portfolio are Imbruvica, currently approved for quite a few indications and marketed in partnership with J&J (JNJ - Free Report) , and Venclyxto/Venclexta, approved to treat chronic lymphocytic leukemia (CLL) and marketed in partnership with Roche (RHHBY - Free Report) .
Several studies on Imbruvica are underway to evaluate the drug alone or in combination across different patient segments. AbbVie is also studying Venclyxto/Venclexta to expand its label to address a broader relapsed/refractory CLL patient population, extend into earlier lines of therapy and cover other hematologic malignancies like multiple myeloma and acute myeloid leukemia (AML).
Notably, other companies are also exploring opportunities to develop novel therapies using the STING activator platform. For instance, AduroBioTech has an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
Further, Aduro has a collaboration and license deal with Novartis for developing and commercializing STING activator candidates in its oncology pipeline.
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>